Atıf İçin Kopyala
Toy M., ÖNDER F. O., İDİLMAN R., Kabacam G., Richardus J. H., Bozdayi M., ...Daha Fazla
EUROPEAN JOURNAL OF HEALTH ECONOMICS, cilt.13, sa.5, ss.663-676, 2012 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
13
Sayı:
5
-
Basım Tarihi:
2012
-
Doi Numarası:
10.1007/s10198-012-0413-8
-
Dergi Adı:
EUROPEAN JOURNAL OF HEALTH ECONOMICS
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus
-
Sayfa Sayıları:
ss.663-676
-
Anahtar Kelimeler:
Chronic hepatitis B, Cost-effectiveness analysis, Antiviral therapy, Turkey, Middle income, NUCLEOSIDE-NAIVE PATIENTS, ADEFOVIR DIPIVOXIL, PEGINTERFERON ALPHA-2A, TREATMENT ALTERNATIVES, COMPENSATED CIRRHOSIS, VIROLOGICAL RESPONSE, LAMIVUDINE TREATMENT, SUSTAINED RESPONSE, NATURAL-HISTORY, RESISTANCE
-
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli:
Hayır
Özet
Chronic hepatitis B (CHB) infection is a serious public health problem due to its potential liver disease sequelae and highly expensive medical costs such as the need for liver transplantation. The aim of this study was to quantify the burden of active CHB in terms of mortality and morbidity, the eligibility of antiviral treatment and to assess various treatment scenarios and possible salvage combinations for cost-effectiveness.